Table 5 . 2-A 
Representative Literature Regarding Administration of Replication Competent 
Adenovirus to Humans by the Respiratory or Oral Routes 
Route/Ref erence 
n 
Virus 
Dose 
Purpose 
Clinical Secruelae 
Shedding 1 Antibodies’ 
Respiratory 
Ginsberg et al. , 1955’ 
24 
Ad4 
unknown 
etiology of 
upper respiratory 
not tested 
75Z 
+ 
nasal 
respiratory 
disease 
symptoms* 
Roden et al. , 1956 
11 
Adi 
10* pfu 
induction of 
mild respiratory 
throat 35Z + 
40Z 
+ 
nasal 
respiratory 
symptoms in 2/11 
disease 
at 2-7 d* 
Bell et al., 1956 
574 
Adl-6 
unknown 
induction of 
none 
not tested 
44-69Z 
+ 
nasal 
respiratory 
inhaled 
disease 
Couch et al. , 1966 
15 
Ad4 
lO'-lO’ 
role of lower 
mild respiratory 
anal 100Z + 
100Z 
+ 
inhaled 
pfu 
respiratory 
symptoms at 6-13 d 
at 3-20 d 
inoculation 
pneumonia in 2* 
throat 100Z + 
at 5-20 d 
Smith et al. , 1970 
58 
Ad4 
10’-10‘ 
prevention of 
none 
nasal 70Z + 
H* 
O 
O 
N 
+ 
nasal 
pfu 
disease with 
intermuscular 
vaccine 
at 2-12 d 
Oral’ 
Couch et al. , 1963 
15 
Ad4 , 7 
o 
H 
J 
O 
H 
oral vaccine 
conjunctivitis 
rectal 100Z + 
>90Z 
+ 
enteric 
pfu 
development 
in 1* 
at 2-24 d 
Chanock et al., 1966 
46 
Ad4 
10’-10‘ 
oral vaccine 
none 
anal 95Z + 
>90Z 
+ 
enteric 
pfu 
dose and safety 
at 21 d 
throat - 
Edmondson et al. , 1966 
134 
Ad 4 
lO’-lO* 
oral vaccine 
none 
anal 95Z + 
>90Z 
+ 
enteric 
pfu 
efficacy 
throat - 
Gutekunst et al. , 1967 
360 
Ad 4 
10*-10 7 
oral vaccine 
none 
anal 100Z + 
100Z 
+ 
enteric 
pfu 
dose and safety 
at 8 d 
throat - 
Rosenbaum et al. , 1968 
65 
Ad3 ,4,7 
10* pfu 
efficacy during 
none 
rectal 95Z + 
90Z 
+ 
enteric 
epidemic Ad 
at 21 d 
throat 30Z + 
at 28 d 
Stanley and Jackson, 1969 
39 
Ad 4 
10’- 10* 
spread of Ad 
none 
rectal 50Z + 
50-100Z 
+ 
enteric 
pfu 
vaccine in. 
at 6 wks 
married couples 
oral 10Z + 
at 6 wks 
Top et al. , 1971c 
55 
Ad4 , 7 
10*- 10* 
oral vaccine 
none 
fecal 80-90Z + 
95Z 
+ 
enteric 
pfu 
safety 
antigenicity 
at 21 d 
Top et al. , 1971a 
88 
Ad4 , 7 
10* pfu 
oral vaccine 
none 
not tested 
65-78Z 
+ 
enteric 
efficacy 
Scott et al. , 1972 
15 
Ad21 
10* pfu 
antibodies 
none 
rectal 90Z + 
90Z 
+ 
enteric 
nasal vs enteric 
'Shedding + = Ad detected in sample after ad administration 
'Antibody + = 4-fold rise in neutralizing ad between pre and post treatment sera in naive individuals 
’Analysis of specimens from previous report: The Commission on Acute Respiratory Diseases, 1947a and ibid . 1947b 
‘Significant clinical sequela occurred in only individuals who had no serum anti-Ad antibodies pretreatment 
’Additional references regarding enteric Ad trials include: Pierce et al., 1966; Peckinbaugh et al. , 1968; Pierce et 
al. , 1968; Griffin et al. , 1970; Top et al. , 1971b; Rosenbaum et al. , 1975 
[736] 
Recombinant DNA Research, Volume 16 
